Save time and jump to the most important pieces.
5 - BIOMERICA INC (0000073290) (Issuer)
4 - BIOMERICA INC (0000073290) (Issuer)
4 - BIOMERICA INC (0000073290) (Issuer)
SC 13G/A - BIOMERICA INC (0000073290) (Subject)
SC 13G/A - BIOMERICA INC (0000073290) (Subject)
SC 13G - BIOMERICA INC (0000073290) (Subject)
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn's Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent Treaty IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease ("GERD")
IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance. This extension was provided because Biomerica currently meets the other continued listing requirement, including the minimum market value of publicly held shares, as well as all other applicable requirements for initial listing on the NASDAQ Capital Marke
Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor's officeWith a simple, at-home finger-prick blood sample, patients can receive a personalized test result identifying potential IBS trigger foods The inFoods® IBS test empowers patients with actionable results to reduce bloating and gastrointestinal pain IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a leading global provider of advanced medical diagnostics, is excited to announce a major enhancement to its inFoods® IBS platform. US consumers can now seamlessly order the inFoods® IBS test directly
8-K - BIOMERICA INC (0000073290) (Filer)
10-Q - BIOMERICA INC (0000073290) (Filer)
DEF 14A - BIOMERICA INC (0000073290) (Filer)
InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina
Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience. Empowering Patients & Physicians Through Self-Collection The inFoods® IBS diagnostic test has made a significant advancement with the introduction of a new patient self-collection system. This innovative system utilizes a simple, minimally invasive finger-stick device that enables patients to collect their own blood samples at home, bypassing the need to visit healthcare facilities. This enhancement enables the inFoods® IBS product to be marketed and provided nationally through teleh
Gainers OneMedNet (NASDAQ:ONMD) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. 23andMe Holding (NASDAQ:ME) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. Cue Health (NASDAQ:HLTH) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. Accelerate Diagnostics (NASDAQ:AXDX) shares increased by 9.01% to $1.39. The market value of their outstanding s
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov
Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica. Mr. Zack Irani will continue to serve as CEO. Mr. Kenny joined the Biomerica Board of Director
Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian BioscienceAs CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion NEWPORT BEACH, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leadin